Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Surgical Devices
transcendmedical.com

See what CB Insights has to offer

Founded Year

2005

Stage

Acquired | Acquired

Total Raised

$87.27M

About Transcend Medical

Transcend Medical is focused on the development of minimally invasive medical devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. Over 4 million people in the U.S. and roughly 60 million worldwide are afflicted with the disease today, and the numbers are expected to grow to nearly 6 million in the U.S. and over 70 million worldwide by the year 2015. The company's CyPass Micro-Stent is a micro-invasive glaucoma stent designed to reduce IOP by enhancing aqueous outflow to the suprachoroidal space, one of the eye's natural, alternative drainage pathways. Implanted in the supraciliary space, the CyPass device bypasses the ciliary body by creating a stented micro-cyclodialysis and enhancing the same outflow system targeted by prostaglandin analogues, the most effective medical treatment for IOP. Targeting suprachoroidal outflow bypasses the trabecular meshwork and Schlemm's canal - drainage paths that may be compromised in glaucomatous eyes. While the CE mark for the device was granted in 2008, the CyPass Micro-Stent is currently for investigational use only.

Transcend Medical Headquarter Location

127 Independence Drive

Menlo Park, California, 94025,

United States

650-223-6600

Latest Transcend Medical News

SG Blocks, Inc. : and Transcend Onsite Care and Execute a Memorandum of Understanding

Mar 31, 2020

0 Message : *Required fields SG Blocks, Inc. (Nasdaq: SGBX) (“SG Blocks” or the “Company”), and Transcend Onsite Care, a cutting edge provider of on-site point of contact medical care, have executed a Memorandum of Understanding to provide joint products and services. SG Blocks is a premier provider of code compliant container based construction and can create turn key solutions for the delivery of Transcend’s array of medical technologies and professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200331005238/en/ (Photo: Business Wire) Products that are expected to be implemented include modular primary care medical units, Covid-19 diagnostic testing units, quarantine living units, as well as drive through testing units at employer onsite clinics and community hospitals. “We can think of no better way to deploy our unique delivery of healthcare solutions and technology than through SG Blocks who shares our passion for disruptive efficiency,” said Mike Ochoa, CEO of Transcend. Ochoa continued, “The world is witnessing a change in how health care can be delivered with options like tele-health, mobile medical units and other point of contact options of care. The de-centralized "meet the client where they are" approach will bring better access to preventive, regular and urgent care. Our short-term goal with our proposed partnership with SG Blocks is to deploy urgent medical care and quarantine living units to meet our customers and patient’s needs on the front lines during this Coronavirus crisis.” The first project planned is two (2) Transcend Medical and Testing Units to be built by SG Blocks and operated by Transcend. The unit will be delivered to a major southern California employer for the initial purposes of providing onsite Covid-19 screening through diagnostic testing and medical care for staff who are required to work during the pandemic. “The expected relationship with Transcend and its network of clients is most exciting for us. We can think of no better purpose for our repurposed containers than fast to market resilient testing and medical clinics as well as living quarters for medical personnel. We believe in Transcend’s disruptive approach to point of care treatment which promotes preventative medicine and reduces the strain on public health infrastructure,” says Paul M Galvin, Chairman & CEO of SG Blocks. About SG Blocks, Inc. SG Blocks, Inc. is a premier innovator in advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and owners in achieving greener construction, faster execution, and stronger buildings of higher value. Each project starts with GreenSteel™, the structural core and shell of an SG Blocks building, and then customized to client specifications. For more information, visit www.sgblocks.com . Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions and includes statements regarding building modular primary care medical units, Covid-19 diagnostic testing units, quarantine living units, as well as drive through testing units at employer onsite clinics and community hospitals, plans to build two (2) Transcend Medical and Testing Units and the expected relationship with Transcend and its network of clients . These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to enter into a definitive agreement with Transcend to provide joint products and services, the Company’s ability to roll-out modular primary care medical units, Covid-19 diagnostic testing units, quarantine living units, as well as drive through testing units at employer onsite clinics and community hospitals, the Company’s ability to build two (2) Transcend Medical and Testing Units for Transcend, the Company’s ability to grow the expected relationship with Transcend and its network of clients, the Company’s ability to capitalize on new commercial and military opportunities, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20200331005238/en/ © Business Wire 2020

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Transcend Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Transcend Medical is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

7,884 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

Transcend Medical Patents

Transcend Medical has filed 55 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • Disorders of sclera and cornea
  • Eye surgery
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/26/2016

3/12/2019

Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Visual system, Disorders of sclera and cornea

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/26/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/12/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Diseases of the eye and adnexa, Eye surgery, Ophthalmology, Visual system, Disorders of sclera and cornea

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.